Table 2

Summary of dosing recommendations for FDA-approved SGLT2 inhibitors

AgentUsual dosing recommendationsRenal dosing recommendations
Canagliflozin• The recommended starting dose is 100 mg once daily, taken before the first meal of the day.
• The dose can be increased to 300 mg once daily in those who require additional glycemic control.• Assess kidney function before initiating and periodically thereafter.
• Limit the dose to 100 mg once daily in patients who have an eGFR of 45 to <60 mL/min/1.73 m2.
• Initiation is not recommended in patients with an eGFR <45 mL/min/1.73 m2.
• Use is not recommended when eGFR is persistently <45 mL/min/1.73 m2.
• Use is contraindicated in patients with an eGFR <30 mL/min/1.73 m2.
Dapagliflozin• The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
• The dose can be increased to 10 mg once daily in those tolerating the medication who require additional glycemic control.• Assess kidney function before initiating and periodically thereafter.
• Initiation is not recommended in patients with an eGFR <60 mL/min/1.73 m2.
• Use is not recommended in patients with an eGFR persistently between 30 and <60 mL/min/1.73 m2.
• Use is contraindicated with an eGFR <30 mL/min/1.73 m2.
Empagliflozin• The recommended starting dose is 10 mg once daily, taken in the morning, with or without food.
• The dose can be increased to 25 mg once daily.• Assess kidney function before initiating.
• Initiation is not recommended if eGFR is <45 mL/min/1.73 m2.
• Discontinue if eGFR is persistently <45 mL/min/1.73 m2.
Ertugliflozin• The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
• The dose can be increased to 15 mg once daily in those tolerating the medication who need additional glycemic control.• Assess kidney function before initiating and periodically thereafter.
• Initiation is not recommended in patients with an eGFR of 30 to <60 mL/min/1.73 m2.
• Continued use is not recommended in patients with an eGFR persistently between 30 and <60 mL/min/1.73 m2.
• Use is contraindicated with eGFR <30 mL/min/1.73 m2.